Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was down 8.6% during mid-day trading on Friday . The stock traded as low as $0.3655 and last traded at $0.3655. Approximately 26,400 shares were traded during mid-day trading, an increase of 258% from the average daily volume of 7,375 shares. The stock had previously closed at $0.40.
Defence Therapeutics Price Performance
The firm’s fifty day simple moving average is $0.39 and its 200 day simple moving average is $0.46.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Read More
- Five stocks we like better than Defence Therapeutics
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
- 3 ETFs For the Coming Genomics Revolution
- The Energy Trade Is Bigger Than Oil Prices: 3 Stocks to Buy and 2 to Sell
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
